Quantum Genomics

the objective of quantum genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class: bapais for brainaminopeptidase a inhibitors. we wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure. high blood pressure remains a major public health concern. quantum genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain aminopeptidase a. the mid-term strategic objective of the company is to sign partnership agreements with major pharmaceutical companies which will take over and bring the products from the bapai technology to the market.